Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia
Peet M, Brind J, Ramchand CN, Shah S, Vankar GK
Schizophrenia research · 182 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2001-04-01 · Schizophr Res · vol. 49 · número 3 · págs. 243–251
- Editorial
- Elsevier BV
- Citado
- 329 citas · más que el 100% de estudios similares · 18.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 68 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Schizophrenia research and treatment · Tryptophan and brain disorders
- Palabras clave
- eicosapentaenoic acid, docosahexaenoic acid
- MeSH
- humans, docosahexaenoic acids, arachidonic acids, antipsychotic agents, pilot projects, double-blind method, schizophrenia, schizophrenic psychology, adult
5 autores
- Malcolm Peet🇬🇧 · autor de correspondenciaNorthern General Hospital; Sheffield Health and Social Care NHS Foundation Trust
- Jan Brind🇬🇧Northern General Hospital
- C.N. Ramchand🇬🇧Northern General Hospital
- Sandeep Shah🇮🇳Sir Sayajirao General Hospital Medical College
- Ganpat Vankar🇮🇳Sir Sayajirao General Hospital Medical College
Resumen
El texto original del estudio, en el idioma en que se publicó.
Evidence that the metabolism of phospholipids and polyunsaturated fatty acids (PUFA) is abnormal in schizophrenia provided the rationale for intervention studies using PUFA supplementation. An initial open label study indicating efficacy for n-3 PUFA in schizophrenia led to two small double-blind pilot studies. The first study was designed to distinguish between the possible effects of two different n-3 PUFA: eicosapentaenoic acid (EPA) and docohexaenoic acid (DHA). Forty-five schizophrenic patients on stable antipsychotic medication who were still symptomatic were treated with either EPA, DHA or placebo for 3 months. Improvement on EPA measured by the Positive and Negative Syndrome Scale (PANSS) was statistically superior to both DHA and placebo using changes in percentage scores on the total PANSS. EPA was significantly superior to DHA for positive symptoms using ANOVA for repeated measures. In the second placebo-controlled study, EPA was used as a sole treatment, though the use of antipsychotic drugs was still permitted if this was clinically imperative. By the end of the study, all 12 patients on placebo, but only eight out of 14 patients on EPA, were taking antipsychotic drugs. Despite this, patients taking EPA had significantly lower scores on the PANSS rating scale by the end of the study. It is concluded that EPA may represent a new treatment approach to schizophrenia, and this requires investigation by large-scale placebo-controlled trials.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.